MoonLake Immunotherapeut...【MLTX】銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

通貨

44.215

買値

44.06

売値

44.40

出来高

18,514

43.35 日の範囲 44.95

35.11 52 週間の範囲 64.98

時価総額

2.824B

前日終値

43.93

始値

44.58

時刻

44.38

最終取引時間

23:00:07

財務取引量

US$ 814,858

VWAP

44.0131

平均取引量 (3 か月)

365,452

発行済株式数

63,869,904

配当利回り

PER

-63.66

1 株当たり利益 (EPS)

-0.69

歳入

純利益

-44.08M

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company engaged in leveraging Nanobody technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases. MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company engaged in leveraging Nanobody technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases.

セクター

Blank Checks

業界

Pharmaceutical Preparations

ウェブサイト

moonlaketx.com

本社

Grand Cayman, Cym

設立

2020

MoonLake Immunotherapeutics is listed in the Blank Checks sector of the ナスダック市場 with ticker MLTX. The last closing price for MoonLake Immunotherapeut... was US$43.93. Over the last year, MoonLake Immunotherapeut... shares have traded in a share price range of US$ 35.11 to US$ 64.98.

MoonLake Immunotherapeut... currently has 63,869,904 shares in issue. The market capitalisation of MoonLake Immunotherapeut... is US$2.81 billion. MoonLake Immunotherapeut... has a price to earnings ratio (PE ratio) of -63.66.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11

MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11 Initiated Phase 3 VELA program of the Nanobody® sonelokimab in...

Form 8-K - Current report

MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic Arthritis

MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic Arthritis Builds upon the...

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	2.425	5.80282364202	41.79	44.95	39.36	414246	41.99797551	CS
4	-0.775	-1.72260502334	44.99	50.53	39.36	392790	44.83870789	CS
12	2.755	6.64495899662	41.46	50.53	37.55	365452	42.57630169	CS
26	-14.185	-24.2893835616	58.4	64.98	37.55	412231	46.33121001	CS
52	-13.495	-23.3841621903	57.71	64.98	35.11	496977	49.50997455	CS
156	31.845	257.437348424	12.37	64.98	4.25	356352	42.03104006	CS
260	31.845	257.437348424	12.37	64.98	4.25	356352	42.03104006	CS

出来高
値上がり率
値下がり率

銘柄コード	株価	出来高
GTHXG1 Therapeutics Inc	US$ 7.075 (66.47%)	15.82M
RRRichtech Robotics Inc	US$ 0.5654 (52.81%)	114.62M
PETQPetIQ Inc	US$ 30.45 (48.03%)	3.18M
ADTXAditxt Inc	US$ 1.4416 (44.59%)	17.75M
IDAIT Stamp Inc	US$ 0.5144 (41.79%)	42.92M
XPONExpion360 Inc	US$ 0.0809 (-68.92%)	42.89M
TLISTalis Biomedical Corporation	US$ 4.50 (-49.89%)	159.27k
DZSIDZS Inc	US$ 0.52801 (-49.23%)	516.06k
VBIVVBI Vaccines Inc	US$ 0.071 (-46.58%)	9.45M
PRCHPorch Group Inc	US$ 1.225 (-28.78%)	1.13M
RRRichtech Robotics Inc	US$ 0.5654 (52.81%)	114.62M
NVDANVIDIA Corporation	US$ 106.86 (2.50%)	59.49M
IDAIT Stamp Inc	US$ 0.5144 (41.79%)	42.92M
XPONExpion360 Inc	US$ 0.0809 (-68.92%)	42.89M
SQQQProShares UltraPro Short QQQ	US$ 9.90 (-5.62%)	40.41M